Peptides
PTD-DBM (5mg)
PTD-DBM peptide, short for Protein Transduction Domain-fused Dishevelled Binding Motif peptide, has been studied for its potential to stimulate follicle growth. PTD is a short sequence of amino acids that may allow the peptide to enter cells, while DBM is a sequence considered to act as a binding agent with Dishevelled (Dvl) proteins, considered highly involved in the Wnt/β-catenin signaling pathway. More specifically, PTD-DBM has been hypothesized by researchers to disrupt the interaction between CXXC5 and Dishevelled (Dvl) proteins, which appears to potentially enhance the activity of the Wnt/β-catenin signaling pathway. Studies hypothesize that this disruption might facilitate an increase in β-catenin activity. This augmented activity was observed to potentially promote hair follicle growth and induce the anagen phase, which is the growth phase of the follicle, in murine models. More precisely, the exposure of PTD-DBM in conjunction with either Wnt3a or valproic acid (VPA)—both agents believed to activate the Wnt/β-catenin pathway—exhibited an apparent synergistic action. This action was speculated by the increased expression levels of β-catenin, alkaline phosphatase (ALP), and proliferating cell nuclear antigen (PCNA). These markers are intrinsically associated with cell proliferation and are indicators of follicle function.(1) PTD-DBM peptide appears to activate the Wnt and β-catenin signaling pathway, a complex network of proteins that may be critical in regulating cell growth, migration, and differentiation during embryonic development and the maintenance of tissues. It is also deemed crucial in processes such as cell fate determination, and appears to play a role in follicle development and cell regeneration. It may stimulate the stem cells in hair follicles, leading to the regeneration of hair and the growth of new follicles. The peptide may also increase blood microcirculation, which is believed to enhance the delivery of nutrients and oxygen to follicles to promote increased rates of growth.(1) Chemical Makeup(2) Molecular Formula: C124H223N61O28S2 Molecular Weight: 3080.7 g/mol Other known titles: Protein Transduction Domain-fused Dishevelled Binding Motif peptide, Hair growth peptide Research and Clinical Studies PTD-DBM and Hair Follicles In an investigation into the biological mechanisms underlying hair loss, coupled with an assessment of potential exposure to compounds structurally similar to PTD-DBM, the study proposed that Prostaglandin D2 (PGD2) may act as a catalyst for hair loss.(3) It purportedly induces this by enhancing the expression of CXXC5, a negative regulator of the Wnt/β-catenin signaling pathway, which plays a pivotal role in developing and regenerating hair follicles. The interaction between CXXC5 and the protein Dishevelled (Dvl) appears to impede this pathway, potentially leading to alopecia. The hypothesis suggests that PGD2 may increase CXXC5 levels through the Bone Morphogenetic Protein (BMP) signaling pathway, which is implicated in the regression of hair follicles during the catagen phase—the transitional stage in hair cycling. This upregulation of CXXC5 by PGD2 seems to inhibit Wnt/β-catenin signaling, which, in turn, may suppress follicle growth. In contrast, PTD-DBM, believed to disrupt the binding between CXXC5 and Dvl, appears to restore the function of the Wnt/β-catenin pathway and thereby may inadvertently promote hair growth. Data supporting this restoration has been published in murine model experiments where the gene for CXXC5 was disabled (knocked out) or the animals were exposed to PTD-DBM, indicating that inhibiting CXXC5 may have counterbalanced the hair loss induced by PGD2. Further, the research points to dihydrotestosterone (DHT), another significant contributor to androgenetic alopecia, intensifying hair loss by stimulating CXXC5 expression through the PGD2-mediated pathways. This suggests a complex interaction where DHT and PGD2 may collaboratively impede hair growth by a concomitant modulation of signaling pathways that involve CXXC5. Intriguingly, the study notes that concurrently inhibiting both CXXC5 and a key enzyme in the β-catenin destruction complex, Glycogen Synthase Kinase-3 beta (GSK-3β), may offer potential in promoting hair growth rather than targeting either component alone. Further studies have investigated the mechanisms behind the peptide’s potential to suppress the interaction between CXXC5 and Dvl proteins.(4) This is presumably achieved by PTD-DBM binding to the PDZ domain of Dvl, thereby possibly preventing the suppressive action of CXXC5 on Wnt/β‐catenin signaling. Furthermore, experimental observations from the study indicated that exposure to PTD-DBM in murine models appeared to have led to hair regrowth and possibly the initiation of wound-induced hair follicle neogenesis (WIHN). In this phenomenon, new hair follicles form as part of the wound-healing process. These outcomes suggest that PTD-DBM might not only promote the anagen phase of the hair cycle but also contribute to the creation of new hair follicles in response to skin injury. PTD-DBM and Bone Regeneration A recent study was conducted on a murine model exposed to PTD-DBM routinely over the course of four weeks.(5) After the completion of the study, it was suggested by the researchers that the peptide may have induced the formation of new bones without histological changes. Hyun-Yi Kim et al. stated, “The inhibitors of Dvl–CXXC5 interaction showed bone-forming effects in ex vivo and in vivo calvaria growth, and […] inhibitor recovered bone loss in postmenopausal model mice. Antibody-based drugs such as anti-Dkk-1 and anti-sclerostin antibodies [...] and PTH-based drugs are expensive [...] Therefore, the development of small-molecule compounds […] would be a valuable addition to osteoporosis [research].” PTD-DBM and Tissue Damage A study presented a detailed examination of the potential mechanisms by which PTD-DBM might facilitate regenerative wound healing, focusing primarily on the modulation of the Wnt/β-catenin signaling pathway.(6) The introduction of PTD-DBM was suggested by researchers to potentially enhance the regenerative healing process. This peptide has been speculated to function by preventing CXXC5 from binding to Dvl proteins, thereby facilitating the activation of the Wnt/β-catenin pathway. Apart from apparent hair growth, such activation is associated with numerous cellular processes deemed crucial for wound healing, including cell proliferation, differentiation, migration, and stem cell activation in tissue regeneration. Moreover, the study notes that the apparent activation of Wnt/β-catenin signaling by PTD-DBM may have led to an increase in markers associated with wound healing and tissue regeneration. This includes the enhancement of fibroblast activity and collagen deposition, which are believed to be essential for the structural rebuilding of damaged tissue. In another study,(7) experimental C3H mice with cutaneous wounds were divided into three groups randomly exposed to the peptide PTD-DBM, valproic acid, or a combination of both. As a control, a separate group of experimental mice was given epidermal growth factor (EGF). After completing the study, it was suggested by the researchers that all three groups appeared to exhibit a gradual improvement in the wound-healing process. However, even more than the EGF alone, the most notable impact was reported in the group presented with the peptide and valproic acid. The research team of Soung-Hoon Lee et al. stated, “Combination [...] with PTD-DBM and VPA significantly induced reepithelialization and enhanced collagen deposition in the large wounds.” PTD-DBM peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References Lee SH, Seo SH, Lee DH, Pi LQ, Lee WS, Choi KY. Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. J Invest Dermatol. 2017 Nov;137(11):2260-2269. doi: 10.1016/j.jid.2017.04.038. Epub 2017 Jun 6. PMID: 28595998. https://pubmed.ncbi.nlm.nih.gov/28595998/ National Center for Biotechnology Information. "PubChem Substance Record for SID 476298902, PTD-DBM Acetate, Source: CreativePeptides" PubChem, https://pubchem.ncbi.nlm.nih.gov/substance/476298902. Accessed 3 May, 2024. Ryu YC, Park J, Kim YR, Choi S, Kim GU, Kim E, Hwang Y, Kim H, Han G, Lee SH, Choi KY. CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2. Cells. 2023 Feb 9;12(4):555. doi: 10.3390/cells12040555. PMID: 36831222; PMCID: PMC9954685. Ryu YC, Lee DH, Shim J, Park J, Kim YR, Choi S, Bak SS, Sung YK, Lee SH, Choi KY. KY19382, a novel activator of Wnt/β-catenin signalling, promotes hair regrowth and hair follicle neogenesis. Br J Pharmacol. 2021 Jun;178(12):2533-2546. doi: 10.1111/bph.15438. Epub 2021 May 5. PMID: 33751552; PMCID: PMC8251890. Hyun-Yi Kim, Sehee Choi, Ji-Hye Yoon, Hwan Jung Lim, Hyuk Lee, Jiwon Choi, Eun Ji Ro, Jung-Nyoung Heo, Weontae Lee, Kyoung Tai No, Kang-Yell Choi, Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy, EMBO Mol Med (2016)8:375-387. https://doi.org/10.15252/emmm.201505714 Choi S, Yoon M, Choi KY. Approaches for Regenerative Healing of Cutaneous Wound with an Emphasis on Strategies Activating the Wnt/β-Catenin Pathway. Adv Wound Care (New Rochelle). 2022 Feb;11(2):70-86. doi: 10.1089/wound.2020.1284. Epub 2021 Apr 20. PMID: 33573472; PMCID: PMC9831250. Lee SH, Kim MY, Kim HY, Lee YM, Kim H, Nam KA, Roh MR, Min do S, Chung KY, Choi KY. The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. J Exp Med. 2015 Jun 29;212(7):1061-80. doi: 10.1084/jem.20141601. Epub 2015 Jun 8. PMID: 26056233; PMCID: PMC4493411. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493411/ Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Cardiogen (20mg)
Cardiogen is considered a peptide bioregulator that possibly regulates fibroblasts, which are cells that play a role in scar formation and tissue repair. The peptide has been widely researched for its potential to interact with the tissues in the cardiovascular system. Still, recent research has suggested that it may also be functional in other tissues via influencing fibroblast activities. Furthermore, scientists believe Cardiogen may increase tumor cell apoptosis (programmed cell death). Chemical Makeup Molecular Formula: C18H31N7O9 Molecular Weight: 489.5 g/mol Structure: H-Ala-Glu-Asp-Arg-OH Other Known Titles: SCHEMBL3194515 Research and Clinical Studies Cardiogen Peptide and Cancer Research Researchers consider the peptide to be an apoptotic reductant in cardiac cells via possibly decreasing p53 expression and may exhibit opposite impacts on tumor cells. The p53 gene produces a protein found inside the nucleus of cells and is considered essential in controlling cell division and cell death. An experiment was conducted on murine models with M-1 sarcoma (indicating it has metastasized to other distant tissues and organs) to determine the tumor-modulating potential of Cardiogen, with apoptosis on tumor cells exceeding normal levels and considered uncontrollable.(1) The results indicated a consequence of necrotic and hemorrhagic development and the improvement of tumor cell apoptosis. The results of the experiment suggested that: “The [concentration-dependent] inhibition of M-1 sarcoma growth after [...] cardiogen was caused by the development of hemorrhagic necrosis and stimulation of tumor cell apoptosis. The parameters of proliferative activity indicate that inhibition of tumor growth was not caused by the direct cytostatic effect of the [peptide] on the tumor. Morphological signs indicate a specific mechanism of cardiogen action, realized through the vascular network of the tumor.” (1) The supposed anti-proliferative action of the peptide suggests that tumor growth inhibition may not result from a cytostatic compound on the tumor. According to morphology, tumor growth inhibition may be mediated by a specific mechanism of action related to blood cell supply. This event may be particular to some tumor cells due to their atypical and increased vascular supply. Cardiogen Peptide and Prostate Cell Aging According to researchers, Cardiogen may significantly increase the expression of signaling factors involved in the differentiation of prostate fibroblasts that typically decrease in senescent cultures.(2) Because these signaling factors are considered to decline in aging and senescent fibroblasts, and Cardiogen appears to restore the levels of these factors, especially in senescent cell cultures, it is posited that the peptide may be a relevant candidate for further research in developing methods to address age-related dysfunctions of prostate cells. Cardiogen Peptide and Cardiomyocytes Proliferation Cardiogen may potentially be able to enter different parts of cells, specifically the cytoplasm, nucleus, and nucleolus. Additionally, researchers have hypothesized that Cardiogen might be able to hinder the breakdown of DNA fragments by endonucleases, which are enzymes involved in DNA processing. To explore this, a study was performed using murine embryonic fibroblast cells.(3) These cells were grown in a laboratory setting, in a culture medium known as DMEM, enriched with approximately 10% embryonic calf serum, and kept in a humid environment. After about five days of growth, the cells were separated into two groups. The first group was left as is, serving as a control, while the second group was exposed to Cardiogen for approximately 30 minutes. It appears that in the cells cultivated with Cardiogen, there was a notable increase in the levels of certain proteins within the cytoplasm (such as actin, vimentin, and tubulin) and in the nucleus (specifically nuclear matrix proteins lamin A and C). Actin, vimentin, and tubulin are integral components of the cytoskeleton, the complex network of protein fibers that provide structure and shape to the cells. Actin forms microfilaments, which are thin, flexible fibers crucial for cellular movement and shape. Vimentin, a type of intermediate filament, offers mechanical support and resilience, particularly vital in cells like fibroblasts that endure stress. Tubulin, on the other hand, is the building block of microtubules, which are thicker, hollow tubes essential for maintaining cell shape, enabling intracellular transport, and facilitating chromosome segregation during cell division. Further, lamin A and C are types of nuclear lamins, which are fibrous proteins providing structural support to the nucleus. They form a mesh-like layer called the nuclear lamina on the inner surface of the nuclear envelope. Lamins are involved in organizing the chromatin (DNA and proteins) within the nucleus, and they also play roles in DNA replication, cell division, and regulating gene expression. The protein increases were roughly 2x - 5x higher with Cardiogen than in the control group. These findings suggest that Cardiogen might be activating the expression of these cytoskeletal and nuclear matrix proteins. A possible explanation might be that Cardiogen may potentially influence the proteins associated with DNA, such as enzymes and transcription factors. This influence may improve the way genes related to these cytoskeletal proteins are accessed for transcription, potentially leading to increased cellular metabolism and the stimulation of cell growth and differentiation.(3) Cardiogen Peptide and Cardiomyocytes Apoptosis Researchers have suggested Cardiogen to increase cardiomyocyte proliferation while possibly decreasing fibroblast growth and development and scar formation, resulting in potential long-term and improved cardiac remodeling. Studies suggest that Cardiogen may reduce the expression of the p53 gene, resulting in a lower apoptosis rate of cardiomyocytes after injury.(4,5) Researchers propose Cardiogen's potential in cardiac tissue: “The tetrapeptide cardiogen demonstrated the great stimulating effect on the proliferation both in tissues from young and old rats. The immunohistochemical study demonstrated a decrease of the p53 protein expression by cardiogen action. This fact can testify that cardiogen inhibits the apoptosis process in the myocardial tissue.”(5) More specifically, the synthetic tetrapeptide Cardiogen appears, based on the study's observations, to potentially play a role in enhancing cell proliferation in murine models of both young and aged specimens. This intriguing finding leads to the tentative hypothesis that Cardiogen might have the capacity to stimulate cell growth in heart muscle tissue. As mentioned, Cardiogen might possibly lead to a reduction in the expression of the p53 protein. This protein, often referred to as the "guardian of the genome," is believed to have crucial roles in controlling the cell cycle and may act as a tumor suppressor, thereby making this a significant point of interest for future cancer research. When active, p53 is considered to have the ability to initiate apoptosis, or programmed cell death. Therefore, a potential decrease in p53 expression as a result of Cardiogen might imply that this compound could inhibit apoptosis in the heart's myocardial tissue. This aspect of the study's findings seems to add an extra layer of complexity and potential significance, warranting further investigation.(5) Another experiment investigating the potential of Cardiogen on cardiomyocyte cell apoptosis was conducted in an experimental murine model of myocardial damage, achieved through the deliberate ligation of the coronary artery.(6) There appears to be research data suggesting that the Cardiogen peptide might significantly reduce mortality following this experimentally induced heart damage. Observations point to a threefold decrease in mortality compared to the control group. Additionally, this peptide may play a role in diminishing necrotic zones within the myocardial tissue, which are considered to be areas of cell death due to a suspected lack of blood flow (ischaemia). It is also proposed that the Cardiogen peptide might assist in preserving the glycogen content in the myocardial tissue. Glycogen, considered to be a vital form of energy storage in cells, when preserved, indicates that the cells might have been better able to maintain their energy reserves in the presence of the Cardiogen peptide. This preservation may potentially enhance the survival and function of cells post-ischaemia. The study further suggests that the Cardiogen peptide may exert a protective effect on mitochondria, which are the structures within cells responsible for energy production. Finally, there is a hypothesis that the Cardiogen peptide might stimulate reparative processes, which may theoretically contribute to repairing the damage caused by ischaemia. Such processes might also potentially improve the metabolism of cardiomyocytes, and reduce cell apoptosis.(6) Cardiogen peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References Levdik NV, Knyazkin IV. Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bull Exp Biol Med. 2009 Sep;148(3):433-6. English, Russian Kheĭfets OV, Poliakova VO, Kvetnoĭ IM. [Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging]. Adv Gerontol. 2010;23(1):68-70 Khavinson, V. K.h, Lin'kova, N. S., Polyakova, V. O., Kvetnoy, I. M., Benberin, V. V., D'yakonov, M. M., & Titkov, Y. S. (2012). Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins. Bulletin of experimental biology and medicine, 153(4), 559–562. https://doi.org/10.1007/s10517-012-1766-9 Grieco P, Gomez-Monterrey I. Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials. Arch Biochem Biophys. 2019 Feb 15;662:15-32. doi: 10.1016/j.abb.2018.11.021 N. I. Chalisova et al., “[The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats],” Adv. Gerontol. Uspekhi Gerontol., vol. 22, no. 3, pp. 409–413, 2009 Khavinson, V., Linkova, N., Dyatlova, A., Kantemirova, R., & Kozlov, K. (2022). Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation. Cells, 12(1), 106. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
P21 (5mg)
The P21 (also identified as P021) is a synthetic peptide designed to mimic the activity of ciliary neurotrophic factor (CNTF) on the brain without triggering an allergic response. CNTF is a protein that promotes the survival and differentiation of various neural cells, including neurons and oligodendrocytes. CNTF has been suggested to exhibit possible neuroprotective and neurodegenerative activity in animal models of neurodegenerative diseases and injuries. Scientists identified CNTF's most active regions based on epitope mapping of neutralizing antibodies to CNTF.(1) This led to the development of Peptide 6, made of 11 amino acids (Ac-VGDGGLFEKKL-NH(2)) and a subsequence of just 4 amino acids called Peptide 6c (Ac-DGGL-NH(2)). These amino acids have been theorized to support hippocampus-dependent learning and memory, increase neurogenesis, and potentially boost neuronal plasticity, as posited in murine models. To improve the stability of the peptide and boost its potential to pass through the blood-brain barrier, the scientists report that they "added adamantane building blocks to the C-terminus or both C- and N-termini of Peptide 6c.” The result is P21, which appears to have the potential to mimic the action of CNTF by activating the CNTF receptor complex and downstream signaling pathways, possibly leading to enhanced cognition, increased proliferation, and neuronal differentiation of adult hippocampal progenitors in murine models. Chemical Makeup Molecular Formula:C30H54N6O5 Molecular Weight: 578.3 g/mol Sequence: Ac-DGGL-adamatanylglycine-NH2 Other Known Titles: P021 Research and Clinical Studies P21 Peptide and Cognitive impairment P21 has been extensively researched in experimental models of cognitive impairment. One notable study examined the impact of P21 peptide exposure in 3xTg-AD murine models between 6-9 months prior to the onset of amyloid beta (Aβ) or tau pathology and during the period of synaptic compensation.(2) The study suggested that P21 appeared to rescue dendritic and synaptic deficits, boost neurogenesis, and reverse cognitive impairment in the 3xTg-AD murine models. The study suggests that P21 may contribute to the mitigation of synaptic deficits and cognitive impairment by potentially providing neurotrophic support during synaptic compensation. According to the researchers, this potential may be achieved via the proposed influence of the peptide on synaptic plasticity, as the peptide appears to increase the levels of several markers essential for synaptic function, such as synapsin, PSD-95, and MAP2. Synapsin may regulate neurotransmitter release, which is considered crucial for communication between neurons. PSD-95 is posited to organize components within postsynaptic densities, ensuring signals are received and processed at synaptic junctions. MAP2 is thought to stabilize microtubules in dendrites, supporting their structure and possibly influencing the formation and maintenance of synaptic connections. Overall, these proteins may support the regulation of neurotransmitter release, potentially stabilizing synaptic changes and maintaining the structural integrity of dendrites. These are essentially nerve cell projections that may receive information from other neurons, called presynaptic neurons, or from the environment. By boosting these markers, P21 is posited to help preserve and enhance synaptic functionality. Another study suggested that the P21 may reduce the natural decline in learning and memory in aged Fisher murine models by inhibiting neurogenesis deficit and possibly increasing the expression of brain-derived neurotrophic factor (BDNF) and restoring synaptic deficits in the cortex and hippocampus.(3) BDNF is posited to be a key protein in the survival and differentiation of neurons and the growth of dendrites. BDNF may work by activating pathways that may prevent cell death and promote the differentiation of progenitor cells into mature neurons, especially in the hippocampus, which may aid in ongoing neurogenesis. BDNF is also thought to be instrumental in enhancing synaptic plasticity. It may help strengthen synaptic connections and modulate neurotransmitter release, facilitating better cognition in models of cognitive impairment. BDNF may also contribute to the structural complexity of neurons by encouraging the growth and branching of dendrites, thereby increasing neural connectivity. The study also indicated that P21 appeared to reduce the concentration of myoinositol, a metabolite that naturally increases in murine models. The study suggests that "stimulating endogenous neuroprotective mechanisms using P21 may be [an interesting research] approach for cognitive aging, Alzheimer's disease, and associated neurodegenerative disorders." P21 Peptide and Alzheimer's Disease (AD) Models Experiments are actively investigating the potential research outcomes of P21 in Alzheimer's models. One study focusing on the potential of P21 suggested that chronic exposure of P21 appeared to possibly reduce the brain level of total tau in aged Fisher rats and possibly also reduce tau levels in the cerebrospinal fluid (CSF) to that of young adult rats.(4) The study also observed that "P21 [may be] blood-brain-barrier-permeable and [may] not induce any detectable immune reaction." The exact mechanism for the apparent reduction of tau protein levels remains unknown. Yet, the researchers posit that the increased BDNF activity may modulate downstream effectors such as glycogen synthase kinase-3 (GSK-3). GSK-3 is posited to be a kinase involved in the phosphorylation of tau. Phosphorylated tau is prone to aggregation, forming neurofibrillary tangles, a hallmark of Alzheimer’s (AD) models. By modulating BDNF levels, P21 may indirectly inhibit GSK-3 activity, potentially reducing tau phosphorylation. Another study investigated the potential of P21 on neurobehavior and AD-like pathology in a transgenic murine model of AD.(5) The compound was presented during the mice's prenatal to early postnatal development. Results suggested that the peptide appeared to rescue cognitive deficits, reduce abnormal accumulation of tau and Aβ plaque load, ameliorate certain markers of postsynaptic deficits, and decrease neuroinflammation in the brain. The purported mechanism may have involved improving PSD-95 levels and cAMP response element-binding protein (CREB) activity, which are considered markers of synaptic function and memory formation. Additionally, P21 may have reduced glial fibrillary acidic protein (GFAP) levels, indicating a potential decrease in neuroinflammation. In another experiment, the researchers investigated the neurotrophic potential of the P21 compound in preventing neurodegeneration, amyloid-β, and tau pathologies in 3xTg-AD murine models.(6) The researchers started P21 exposure during the period of synaptic compensation several months before the appearance of any overt pathology. They observed that P21 initiated during this period might have prevented neurodegeneration, Aβ, and tau pathologies, rescued episodic memory impairment, and may have potentially reduced the mortality rate. One trial also investigated the potential of P21 on cognitive function and synaptic plasticity in a transgenic murine model of AD.(7) Results indicated that the peptide might mitigate cognitive impairment, increase expressions of pCREB and BDNF, and ameliorate synaptic protein deficit in the murine models. These actions may lead to the activation of three key signaling pathways: PLC/PKC, MEK/ERK, and PI3K/Akt. These pathways are purported to play a potential role in neuronal survival, growth, and synaptic plasticity. By enhancing these signaling cascades, the peptide is posited to improve synaptic protein expression. The study also suggests that P21 might potentially rescue synaptic deficits and cognitive impairment in familial AD and related tauopathies during early development. P21 Peptide and Macular Degeneration Age-related macular degeneration (AMD) affects the macula, the central part of the retina responsible for central vision. It is considered a common neurodegenerative disease that may lead to vision loss at its end stage. Recent research has suggested that consistent exposure to the neurotrophic peptidergic compound may help prevent the occurrence of AMD pathology. A study conducted in aged and 3xTg-AD murine models reported that chronic presentation of P21 appeared to possibly prevent several pathological changes associated with AMD.(8) The study reported identifying photoreceptor degeneration, lipofuscin granules, vacuoles, atrophy in retinal pigment epithelium (RPE), and Bruch's membrane (BM) thickening. The study also reported a rosette-like structure formation in aged murine models, a hallmark of AMD pathology. Microgliosis and astrogliosis, inflammatory responses in the retina, were also observed in different retinal layers. Furthermore, the study indicated that total tau, phosphorylated tau, Aβ/APP, and VEGF appeared widely distributed in the sub-retina of aged and 3xTg murine models. These molecules are associated with Alzheimer's disease pathology, and their presence suggests that retinal changes associated with aging and Alzheimer's disease may share some common features. Importantly, consistent exposure to P21 for three months in rats and 18 months in 3xTg murine models appeared to ameliorate the pathological changes described above. P21 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References Li, B., Wanka, L., Blanchard, J., Liu, F., Chohan, M. O., Iqbal, K., & Grundke-Iqbal, I. (2010). Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS letters, 584(15), 3359–3365. https://doi.org/10.1016/j.febslet.2010.06.025 Baazaoui, N., & Iqbal, K. (2017). Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimer's research & therapy, 9(1), 45. https://doi.org/10.1186/s13195-017-0273-7 Bolognin, S., Buffelli, M., Puoliväli, J., & Iqbal, K. (2014). Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiology of aging, 35(9), 2134–2146. https://doi.org/10.1016/j.neurobiolaging.2014.02.017 Khatoon, S., Chalbot, S., Bolognin, S., Puoliväli, J., & Iqbal, K. (2015). Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound. Journal of Alzheimer's disease : JAD, 47(3), 557–564. https://doi.org/10.3233/JAD-142799 Wei, W., Wang, Y., Liu, Y., Dai, C. L., Tung, Y. C., Liu, F., & Iqbal, K. (2020). Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. Alzheimer's research & therapy, 12(1), 102. https://doi.org/10.1186/s13195-020-00666-7 Baazaoui, N., & Iqbal, K. (2017). Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound. Journal of Alzheimer's disease : JAD, 58(1), 215–230. https://doi.org/10.3233/JAD-170075 Wei, W., Liu, Y., Dai, C. L., Baazaoui, N., Tung, Y. C., Liu, F., & Iqbal, K. (2021). Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction. Journal of Alzheimer's disease : JAD, 82(2), 631–646. https://doi.org/10.3233/JAD-201599 Liu, Y., Wei, W., Baazaoui, N., Liu, F., & Iqbal, K. (2019). Inhibition of AMD-Like Pathology With a Neurotrophic Compound in Aged Rats and 3xTg-AD Mice. Frontiers in aging neuroscience, 11, 309. https://doi.org/10.3389/fnagi.2019.00309 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Melanotan 2 (10mg)
Melanotan 2 peptide is a synthetic compound, which is an analog of the α-melanocyte-stimulating hormone.(1) The peptide is a cyclic heptapeptide that appears to have a modified affinity towards the receptors that the endogenous hormone may interact with. In addition to possibly stimulating melanogenesis (the production of melanin pigment) in dermal cells, this peptide may have increased affinity towards other receptors that play a role in the regulation of appetite and various types of arousal.(2) Overview Melanotan 2 likely serves as a non-selective agonist with the potential to bind with four out of the five different subtypes of melanocortin receptors (MC-R).(3) Depending on the localization, the receptor-Melanotan 2 bond may induce different actions. Namely, the four receptors that Melanotan 2 may interact with include: The melanocortin 1 receptor (MC1R) may be expressed in melanocytes, which are cells found in tissues such as dermal tissues, hair, and possibly cells and tissues found in the eye. The melanocortin 3 receptor (MC3R) might be found in a range of tissues, potentially including the brain and the placenta. Initial observations suggest that MC3R might be involved in modulating appetite under certain experimental conditions. The melanocortin 4 receptor (MC4R) may be localized within the central nervous system, perhaps in the hypothalamus. Some early indications suggest that this receptor may impact neurons that are believed to have some influence over mating behaviors and general arousal. The melanocortin 5 receptor (MC5R) appears to be distributed across multiple tissues, although what role it might serve remains unclear. For example, the potential interaction between Melanotan 2 and the MC1Rs may lead to increased production of eumelanin, which causes darkening of the epidermal layer’s pigment.(4) On the other hand, when Melanotan 2 binds with the MC4R, it may induce supraspinal centers in the brain, which may lead to increased libido. These signals may then be carried to the sympathetic and parasympathetic centers in the spinal cord and thoracolumbar region.(3) Chemical Makeup Other Known Titles: MT-II Molecular Weight: 1024.19 g/mol Molecular Formula: C50H69N15O9 Research and Clinical Studies Melanotan 2 Peptide and Nerve Cell Regeneration Research(5) in a murine model of an induced peripheral nerve injury has been employed to investigate the neurotrophic potential of Melanotan 2. 48 hours after half of the murine models were presented with the peptide, it was noted that the Melanotan 2 research models appeared to indicate a recovery in their sensory function. Furthermore, when the murine models were presented with a chemotherapeutic compound, Melanotan 2 appeared to exhibit neuroprotective properties, which protected the nerves from the compound's induced neurotoxicity to a certain extent. This potential is posited to be mediated via the MC4 receptors, which might even promote neurite outgrowth and possibly support the intrinsic capacity of neuronal tissue to recover after injury. Although the exact signaling pathways are not fully understood, it is often suggested that the pro-opiomelanocortin (POMC)-derived melanocortin peptides, including compounds analogous to a-melanocyte-stimulating hormone (a-MSH), may influence neuronal structures by increasing the number and length of neurites and potentially promoting nerve sprouting in damaged regions. Since Melanotan 2 is considered a potent melanocortin receptor agonist, it may trigger a cascade of intracellular events that theoretically lead to a better-supported ability of nerve fibers to regenerate after various forms of insult, as well as a partial protective response against toxic neuropathic conditions. Therefore, the researchers concluded that they “observed that Melanotan-II also possesses neuroprotective properties, as it partially protected the nerve from a toxic neuropathy induced by cisplatin.” Melanotan 2 Peptide and Arousal Neurosignaling In a clinical study,(6) Melanotan 2 has been suggested to induce increased arousal neuron signaling in more than 80% of cases, compared to only 20% success with a placebo. This research peptide may act via the MC4 receptors and downstream of established neuromodulators, including dopaminergic and oxytocinergic signals, possibly integrating their actions within discrete hypothalamic centers. These regions are thought to coordinate various homeostatic and motivational behaviors, and the introduction of an agonist like Melanotan 2 may potentially reframe the balance of neuronal activity. These researchers also posit that the involvement of MC5 receptors in certain peripheral glands may potentially provide a parallel route that links central neuro signaling with peripheral modulatory factors. However, this remains an area where mechanisms are only hypothesized. Melanotan 2 Peptide and Neurodevelopmental Modulation Researchers have said that Melanotan 2 may potentially influence aberrant neural mechanisms by possibly stimulating populations of neurons that may govern social cognition through endogenous oxytocinergic signaling.(7) These MC4R-sensitive circuits, potentially located in regions such as the paraventricular nucleus of the hypothalamus, might release endogenous oxytocin in response to Melanotan 2, possibly recalibrating imbalanced neurochemical activity thought to underlie key aspects of social impairment. This oxytocin release may, in turn, modulate neurotransmission involving serotonin, glutamate, dopamine, and GABA, all of which are implicated in shaping social adaptation. By engaging these systems, Melanotan 2 may alter the functional connectivity of cortical and subcortical networks—regions including, for instance, the anterior cingulate cortex—where oxytocin receptor distribution may differ in atypical neurodevelopmental contexts. In doing so, researchers have been able to hypothesize that Melanotan 2 might restore or modify synaptic communication and synaptic plasticity, which may go so far as to reshape the underlying neuroarchitecture. Melanotan 2 Peptide and Models of Sunless Tanning Melanotan 2 may increase melanin production and thereby induce darker pigmentation without the need for ultraviolet irradiation by engaging the MC1R on melanocytes.(8) Moreover, the peptide's cyclic structure supports a more prolonged metabotropic activity compared to other MSH analogs. Although the precise intracellular signaling cascades remain incompletely understood, current data suggest that receptor interactions might lead to the elevated synthesis of eumelanin. This might offer a potential pathway for the development of sunless tanning models in a controlled research environment. Specifically, researchers have made comments about their observation of outcomes in research models, such as “increased [darkened] pigmentation in the face, upper body, and buttock” in experimental settings. Melanotan 2 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Ryakhovsky, Vladimir V et al. “The first preparative solution phase synthesis of Melanotan II.” Beilstein Journal of Organic Chemistry vol. 4 (2008): 39. doi:10.3762/bjoc.4.39. https://pubmed.ncbi.nlm.nih.gov/19043625/ Mac E. Hadley, Discovery that a melanocortin regulates sexual functions in male and female humans, Peptides, Volume 26, Issue 10, 2005, Pages 1687-1689, ISSN 0196-9781, https://doi.org/10.1016/j.peptides.2005.01.023 King, Stephen H et al. “Melanocortin receptors, melanotropic peptides and penile erection.” Current topics in medicinal chemistry vol. 7,11 (2007): 1098-1106. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694735/ Peters, Björn, et al. “Melanotan II: a possible cause of renal infarction: review of the literature and case report.” CEN case reports vol. 9,2 (2020): 159-161. doi:10.1007/s13730-020-00447-z. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148395/ Ter Laak, Mariël P, et al. “The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat.” European Journal of Pharmacology vol. 462,1-3 (2003): 179-83. doi:10.1016/s0014-2999(02)02945-x. https://pubmed.ncbi.nlm.nih.gov/12591111/ Wessells, H et al. “Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.” International journal of impotence research vol. 12 Suppl 4 (2000): S74-9. doi:10.1038/sj.ijir.3900582. https://pubmed.ncbi.nlm.nih.gov/11035391/ Minakova E, Lang J, Medel-Matus JS, Gould GG, Reynolds A, Shin D, Mazarati A, Sankar R. Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. PLoS One. 2019 Jan 10;14(1):e0210389. Doi: 10.1371/journal.pone.0210389. PMID: 30629642; PMCID: PMC6328175. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84. doi: 10.1016/0024-3205(96)00160-9. PMID: 8637402. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
GHK Basic (50mg)
GHK Basic is a tripeptide containing the amino acid sequence glycyl-histidyl-lysine. This short-chain peptide is considered to help cell communication for a wide range of actions. Research on the GHK has yielded a variety of potential biological activities, including possible stimulation of blood vessels and nerve outgrowth, increasing elastin, glycosaminoglycan, collagen synthesis, and possibly promoting dermal fibroblast functions. The tissue repair potential of this peptide has been researched in lung connective tissue, bone tissue, liver, stomach lining, and skin.(1) The peptide has also been suggested to play some role in DNA repair, lung protection, fibroblast reactivation, and possibly in suppressing proinflammatory and pro-aging molecules like NFκB. GHK Basic has also been suggested to have the potential to repair protective proteins in the skin barrier. Chemical Makeup(2) Molecular Formula: C14H24N6O4 Molecular Weight: 340.4 g/mol Research and Clinical Studies GHK Basic and Skin Cell Regeneration According to research, adding plasma to aged liver tissue may cause the aged tissues to produce proteins identical to those seen in plasma.(2,3,4) Several studies have suggested that GHK proteins may increase collagen production, glycosaminoglycans, and small proteoglycans such as decorin. Furthermore, research indicates that GHK might also influence the activities of metalloproteinases – enzymes that initiate extracellular matrix protein breakdown – and antiprotease actions. This GHK action may regulate skin protein breakdown, potentially preventing damaged protein accumulation and excessive proteolysis. GHK Basic and Wound Healing Animal model studies suggest the peptide may promote wound healing through two possible mechanisms. First, GHK, when combined with a high-concentration helium-neon laser, was reported to accelerate wound contraction and granular tissue production while hosting antioxidant enzyme activities and increasing blood vessel growth.(5) Second, wound healing in control and diabetic murine models was reported to be improved by collagen dressing loaded with GHK. The researchers commented that “the wounds were almost closed by 99.39% when [exposed to] biotinylated GHK-loaded films on day 21 when compared to 69.49% wound closure for plain films.” Increased glutathione and ascorbic acid levels were found, as well as enhanced epithelialization and increased collagen synthesis, fibroblasts, and mast cell activation in wounds.(6) GHK and its analogs may also have potential in follicular stimulation and growth. Researchers reported the naturally occurring copper complex GHK-Cu to increase vascular endothelial growth factor production, possibly leading to growth and new blood vessel formation. In one murine experiment, the copper-containing version of GHK appeared to mediate a significant decrease in wound area compared to placebo. Wounds exposed to the copper-containing version of GHK were suggested to have lower concentrations of the pro-inflammatory markers MMP-2, MMP-9, and TNF-alpha.(7) Notably, the copper-containing versions of GHK may also help reduce some potential complications that may negatively impact wound healing, such as colonization of the wound with pathogenic microorganisms. A study of GHK on diabetic ulcers stated that the peptide may have sped up wound closure in larger ulcers and reduced the risk of wound infections compared to the study group that received only a vehicle (placebo). More specifically, the researchers commented that “the enhancement of wound closure was more pronounced (median of 89.2% compared with −10.3% for vehicle; p < 0.01) in larger (greater than 100 mm2 initial area at study entry) plantar ulcers.” The incidence of ulcer infections was also significantly lower, equal to about 7% in the GHK group compared to 34% for vehicle.(8) GHK Basic and Anti-inflammatory, Antioxidant Activities GHK has been suggested to exhibit potential antioxidant action, specifically in its posited interaction with lipid peroxidation, a process which produces adverse free radicals capable of DNA, protein, and cell damage. GHK may help minimize this damage by binding the byproducts of this process.(9) The specific radicals suggested by the scientists include 4-hydroxynoneal, acrolein, malondialdehyde, and others. Further, it has also been proposed that GHK might play a role in diminishing the release of iron from ferritin, an agent that catalyzes lipid peroxidation. More specifically, studies have suggested that GHK could potentially limit the creation of iron compounds in injured tissues, thereby mitigating inflammation.(10) It is believed that GHK's mechanism may involve attaching to ferritin's iron release pathways, potentially decreasing -Fe release by an estimated 87%, which might, in theory, curb inflammation and oxidation in affected tissues. The anti-inflammatory potential of GHK might benefit specific tissues like the lungs. An experiment in murine models examined GHK's impact on lipopolysaccharide-induced lung inflammation.(11) The findings suggest that GHK may lower the generation of reactive oxygen species and inflammatory cytokines while boosting the efficacy of antioxidant enzymes. It is thought to hinder the activation of NF-κB and p38 MAPK signaling pathways, reducing TNF-1 and IL-6 levels. Moreover, the study noted that GHK seemed to mitigate lung tissue alterations and lessen inflammation in murine models suffering from lung damage. More specifically, the peptide was reported to have decreased the influx of inflammatory cells into the lung tissue in cases of experimentally induced acute lung injury in these models. GHK might also contribute to alleviating oxidative stress in lung tissues related to smoke exposure. Research indicates that GHK may suppress oxidative stress in alveolar epithelial cells through the upregulation of Nrf2 expression.(12) GHK Basic and Fibrinogen High fibrinogen levels are considered to increase blood viscosity by increasing rouleaux formation, which research suggests are risk factors for cardiovascular disease.(13) Studies on the peptide generally suggest that it has the potential to inhibit fibrinogen synthesis, thereby possibly lowering the risk of coronary occurrences. GHK Basic peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018 Jul 7;19(7):1987 National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 378611, Cu-GHK. Retrieved March 17, 2024 from https://pubchem.ncbi.nlm.nih.gov/compound/Cu-GHK. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. DOI: 10.1155/2015/648108. Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020 Mar 27;2(1):58-61. DOI: 10.31491/apt.2020.03.014. Gul, N. Y., Topal, A., Cangul, I. T., & Yanik, K. (2008). The effects of tripeptide copper complex and helium-neon laser on wound healing in rabbits. Veterinary dermatology, 19(1), 7–14. https://doi.org/10.1111/j.1365-3164.2007.00647.x Alven, S., Peter, S., Mbese, Z., & Aderibigbe, B. A. (2022). Polymer-Based Wound Dressing Materials Loaded with Bioactive Agents: Potential Materials for the Treatment of Diabetic Wounds. Polymers, 14(4), 724. https://doi.org/10.3390/polym14040724 Canapp, S. O., Jr, Farese, J. P., Schultz, G. S., Gowda, S., Ishak, A. M., Swaim, S. F., Vangilder, J., Lee-Ambrose, L., & Martin, F. G. (2003). The effect of tripeptide-copper complex on healing of ischemic open wounds. Veterinary surgery : VS, 32(6), 515–523. https://doi.org/10.1111/j.1532-950x.2003.00515.x Mulder, G. D., Patt, L. M., Sanders, L., Rosenstock, J., Altman, M. I., Hanley, M. E., & Duncan, G. W. (1994). Enhanced healing of ulcers in patients with diabetes by treatment with glycyl-l-histidyl-l-lysine copper. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 2(4), 259–269. https://doi.org/10.1046/j.1524-475X.1994.20406.x Cebrián, J., Messeguer, A., Facino, R. M., & García Antón, J. M. (2005). New anti-RNS and -RCS products for cosmetic treatment. International journal of cosmetic science, 27(5), 271–278. https://doi.org/10.1111/j.1467-2494.2005.00279.x Miller, D. M., DeSilva, D., Pickart, L., & Aust, S. D. (1990). Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Advances in experimental medicine and biology, 264, 79–84. https://doi.org/10.1007/978-1-4684-5730-8_11 Park, J. R., Lee, H., Kim, S. I., & Yang, S. R. (2016). The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget, 7(36), 58405–58417. https://doi.org/10.18632/oncotarget.11168 Zhang, Q., Yan, L., Lu, J., & Zhou, X. (2022). Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Frontiers in molecular biosciences, 9, 925700. https://doi.org/10.3389/fmolb.2022.925700 Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:151479. DOI: 10.1155/2014/151479. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Cartalax (20mg)
Cartalax, or AED or T-31 peptide, is a synthetic peptide designed to target specific biological pathways that may have implications in cellular aging. The peptide is based on the sequence of amino acids derived from the alpha-1 chain of type XI collagen (hence AED, standing for the amino acid sequence Alanine-Glutamate-Aspartate). It has also been isolated from kidney extracts containing polypeptides. Peptides like Cartalax are often investigated for their potential to modulate biological processes, including inflammation and cartilage repair, which are significant factors in osteoarthritis. More specifically, it is classified among the Khavinson peptides and has been suggested by researchers to act as a bioregulator. Chemical Makeup Molecular formula: C12H19N3O8 Molecular weight: 333.29 g/mol Sequence: Ala-Glu-Asp Other known titles: AED, T-31, SCHEMBL5324601 Research and Clinical Studies The data presented here distills the most recent findings from preclinical studies on the potential of Cartalax, as evidenced across a spectrum of experimental frameworks. Cartalax and Fibroblasts The peptide Cartalax, when explored for its impacts on skin fibroblasts, appears to hold properties that may potentially influence the aging process of these cells in culture.(1) Cartalax has been suggested to potentially play a role in several critical cellular processes that are pivotal for fibroblast function and longevity. Firstly, Cartalax may contribute to the proliferation of fibroblasts, as suggested by its potential enhancement of Ki-67 expression. Ki-67 is a well-known marker associated with cell proliferation. The expression of Ki-67 typically decreases during the aging of fibroblasts in culture. The fact that Cartalax seemingly promotes the levels of Ki-67 implies that this peptide may encourage fibroblast growth or increase their replicative lifespan, potentially combating the natural decline in cell division over time. Additionally, the apparent action of Cartalax on the expression of CD98hc is noteworthy. CD98hc is implicated in the regeneration and aging processes of cells. The increased expression of CD98hc in the presence of Cartalax may suggest a role in enhancing the regenerative capacity or possibly sustaining the vitality of aging fibroblasts. By promoting the expression of CD98hc, Cartalax may help maintain cellular functions that usually wane as cells age. The study also indicates that Cartalax potentially suppresses caspase-3 activity, which indicates its potential to inhibit apoptosis (cell death). Apoptosis, the programmed cell death that is a natural part of an organ's renewal and homeostasis, may be detrimental when excessive or dysregulated. During the aging of cell cultures, an increase in apoptosis, or programmed cell death, is common. Cartalax's apparent suppression of caspase-dependent apoptosis could suggest that this peptide may allow fibroblasts to avert the increased incidence of cell death associated with aging, potentially contributing to an extended cellular lifespan. Moreover, the researchers commented that the peptide “reduced the level of apoptosis in young and aged cultures.” Cartalax was also observed to inhibit the synthesis of MMP-9. MMP-9 is an enzyme involved in the remodeling of the extracellular matrix, and its increased activity is often associated with aging in fibroblasts. By inhibiting MMP-9 synthesis, Cartalax might help preserve the integrity of the extracellular matrix, possibly preventing or mitigating the degenerative changes that typically occur with aging.(1) Ultimately, Cartalax has been suggested to regulate several markers in this replicative aging murine model of skin fibroblasts, such as Ki67 (a protein associated with proliferation), CD98hc (a glycoprotein), Caspase-3 (an apoptosis marker), and MMP9 (an enzyme involved in the degradation of extracellular matrix). Since chondrocytes (cartilage cells) share structural and functional characteristics with fibroblasts, these findings might suggest that Cartalax could have reparative properties in cartilage tissues as well.(2) Cartalax and Kidney Cells The peptide Cartalax may carry the potential to influence kidney cell regeneration favorably. This influence is posited upon observations in organotypic kidney tissue cultures taken from both young and older murine models, where the presence of Cartalax was associated with a promotion of cellular proliferation. This proliferative action was apparently indicated by an increased expression of the marker Ki-67, which is commonly used to gauge cell proliferation. Furthermore, Cartalax may also contribute to a decrease in apoptotic processes within the kidney cells. The peptide Cartalax appears to potentially mitigate this by reducing the expression of the proapoptotic peptide p53. This protein, when expressed in high levels, is suggested to facilitate the process of apoptosis, and its down-regulation by Cartalax suggests that the peptide might help maintain cellular integrity and prolong cell survival. Thus, the presented information in this study also suggests Cartalax as a molecule of interest for its potential in the aging process of kidney cells.(3) Other studies, such as another trial in aging renal cell cultures, further elaborated this suggestion. The study in question suggested that Cartalax may have an impact by promoting cell proliferation and possibly modifying the expression of several critical markers associated with aging. Specifically, the peptide is suggested to potentially decrease the expression of aging markers such as p16, p21, and p53, which are proteins frequently linked to the advancement of cellular senescence—the state in which cells stop dividing and growing. Beyond the suppression of these markers, Cartalax is also suggested to potentially increase the expression of SIRT-6, a protein that plays a significant role in DNA repair and in maintaining genomic stability, known to wane with age. The promotion of SIRT-6 by Cartalax might contribute to slowing down the aging process in renal cells, as a reduction in SIRT-6 is implicated in the acceleration of cellular aging. The study further suggests that the protective actions of Cartalax on kidney cells may be attributable to the peptide's interactions with DNA. It appears that Cartalax may form energetically favorable complexes with specific sequences of DNA, particularly d(ATATATATAT)2 in the minor groove. This interaction is hypothesized to be a catalyst for the changes observed in gene expression, including those genes that code for aging markers in renal cells. By potentially affecting gene expression, Cartalax might aid in preserving the health and function of kidney cells, possibly delaying aging. The development of experimental data models to understand the interaction between Cartalax and DNA sequences emphasizes the intricacies of the underlying mechanisms. The proposition that this interaction may cause gene expression changes offers a novel insight into how particular peptides might influence the aging process at the molecular level.(4) Cartalax and Cellular Aging Apart from its potential on fibroblasts and kidney cell cultures, Cartalax has also been researched on its potential impact on bone marrow mesenchymal stem cells. More specifically, the peptide Cartalax could potentially exert a notable influence on the cellular mechanisms related to aging in bone marrow mesenchymal stem cells, based on observations from a study examining gene expression levels in cells that are undergoing an aging process in two distinct environments: "passages" or during their proliferation phase, and "stationary" or non-proliferating conditions. As cells age, they go through various stages, often described as "passages" in cell culture, which denote the number of times the cells have been divided and subcultured. Eventually, cells enter a "stationary" phase of growth, commonly associated with cellular senescence, where they no longer divide but are still metabolically active. This phase may reflect the aging process of cells. Cartalax might play a role in the upregulation of the insulin-like growth factor 1 (IGF1) gene in both aging models, potentially enhancing its expression by approximately 3.5 to 5.6 fold. The IGF1 protein is known for its involvement in cellular growth and development, and its increased expression might suggest a role for Cartalax in promoting growth-related cellular functions, which could possibly counteract certain aspects of the cellular aging process. The study also noted an eightfold increase in the expression of the TERT gene, which encodes the catalytic subunit of the enzyme telomerase, in "stationary" aging conditions. However, the text provided does not specify the action of Cartalax on TERT expression. Since telomerase plays a crucial role in maintaining telomere length and thus cellular longevity, any potential modulation by Cartalax might have significant implications for cellular aging. Further, Cartalax appeared to stimulate the expression of the NFκB gene in both aging models. NFκB is a protein complex that functions in various cellular processes, including inflammation, immunity, and cellular survival. The stimulation of NFκB by Cartalax could imply a potential influence on the cellular stress response pathways, which are intimately linked to the aging process. Further, the authors commented that the “peptide does not affect TNKS2 in “passages,” but inhibits it in “stationary”aging culture.” TNKS2 refers to "Tankyrase 2," which is a member of the poly(ADP-ribose) polymerase (PARP) family of enzymes. Tankyrases, including TNKS2, play a crucial role in various cellular processes, such as regulation of Wnt signaling, telomere maintenance, and regulation of vesicle trafficking. Particularly, the role of maintaining telomeres is thought to mediate the potential anti-aging impact of the interaction between Cartalax and TNKS2.(5) Cartalax peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Lin'kova, N. S., Drobintseva, A. O., Orlova, O. A., Kuznetsova, E. P., Polyakova, V. O., Kvetnoy, I. M., & Khavinson, V. K.h (2016). Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bulletin of experimental biology and medicine, 161(1), 175–178. https://doi.org/10.1007/s10517-016-3370-x Linkova, N., Khavinson, V., Diatlova, A., Myakisheva, S., & Ryzhak, G. (2023). Peptide Regulation of Chondrogenic Stem Cell Differentiation. International Journal of Molecular Sciences, 24(9), 8415. Chalisova, N. I., Lin'kova, N. S., Nichik, T. E., Ryzhak, A. P., Dudkov, A. V., & Ryzhak, G. A. (2015). Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. Bulletin of experimental biology and medicine, 159(1), 124–127. https://doi.org/10.1007/s10517-015-2906-9 Khavinson, V. K.h, Tarnovskaia, S. I., Lin'kova, N. S., Poliakova, V. O., Durnova, A. O., Nichik, T. E., Kvetnoĭ, I. M., D'iakonov, M. M., & Iakutseni, P. P. (2014). Advances in gerontology = Uspekhi gerontologii, 27(4), 651–656. Ashapkin, V., Khavinson, V., Shilovsky, G., Linkova, N., & Vanuyshin, B. (2020). Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Molecular biology reports, 47(6), 4323–4329. https://doi.org/10.1007/s11033-020-05506-3 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
CJC-1295 & GHRP-2 Blend (10mg)
Research indicates that GHRP-2 and CJC-1295 peptides may act on separate receptors, potentially enhancing the release of growth hormone (GH) from the anterior pituitary. CJC-1295 is a molecular compound that exhibits an apparent binding affinity for the growth hormone-releasing hormone (GHRH) receptors, potentially inducing growth hormone release by pituitary cells. CJC-1295 is derived from GHRH 1-29, which is considered to represent the functional sequence of the initial 29 amino acids of GHRH. The peptide CJC-1295 has undergone tetra substitution and modification through the addition of a drug affinity complex (DAC) component. This DAC component appears to bind to plasma proteins and may enhance the pharmacokinetic profile of CJC-1295.(1) Growth Hormone Releasing Peptide 2 (GHRP-2) is a synthetic hexapeptide composed of six amino acids. Research teams have observed this peptide to bind to the ghrelin or growth hormone secretagogue 1a receptors (GHS-R1a), which are present in the hypothalamus and the pituitary gland. Consequently, GHRP-2 has been suggested by researchers to stimulate the production of growth hormones in pituitary cells that express the GHS-R1a receptor.(2) By stimulating different receptors through distinct biochemical pathways, these peptides are believed to synergistically elevate GH release from the anterior pituitary beyond the individual capacities of each peptide. Chemical Makeup(3)(4) Molecular Formula CJC-1295: C152H252N44O42 GHRP-2: C45H55N9O6 Molecular Weight CJC-1295: 3367.9 g/mol GHRP-2: 817.9 g/mol Sequence CJC-1295: L-tyrosyl-D-alanyl-L-alpha-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-alpha-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-argininamide GHRP-2: D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide Other Known Titles CJC-1295: GRF 1-29 albumin conjugate, GHRH Derivative GHRP-2: Pralmorelin, GPA-748 Research and Clinical Studies CJC-1295 & GHRP-2 Blend and Growth Hormone Secretion According to research teams exploring the topic, GHRP-2 may possess a strong affinity towards the growth hormone secretagogue 1a receptor (GHS-R1a) in the hypothalamus and pituitary gland, whereas CJC-1295 may possibly interact with the growth hormone-releasing hormone receptor (GHRH-R) in the pituitary gland. Studies suggest that the influence of this peptide blend may increase plasma growth hormone (GH) levels, indicating their potential to enhance GH release. Possible sustained release of this blend also appears to extend the peptide half-life, potentially prolonging GH secretion compared to individual peptide presentation. As per studies, it has been reported that “basal GH levels may increase by 7.5-fold,” which appears to have contributed to “an overall increase GH secretion by 46%” (1) Though acting on different receptors, research suggests that synergistically, these peptides may promote “pulsatile release of growth hormones that is subject to negative feedback, and may prevent supratherapeutic levels of GH and their sequelae” (5) It has been hypothesized that GHRH-mimetics such as CJC-1295 and the secretagogue GHRP-2 may potentially exhibit synergistic effects in regard to their apparent stimulation of growth hormone secretion. Interestingly, the combination of both GHRH-mimetic and GHRP-2 was observed to induce a 54-fold increase in pulsatile GH secretion compared to controls. Moreover, GHRP-2 appeared to decrease the time to maximal GH secretion with a median time reduction of 43%. GHRP-2 was reported to lead to a 47-fold increase in pulsatile GH secretion, while GHRH-mimetics appear to lead to only a 20-fold increase.(6) CJC-1295 & GHRP-2 Blend and Metabolism of Muscle and Fat GHRP-2 and CJC-1295 peptides, albeit via different proposed mechanisms, appear to stimulate GH release from the pituitary cells, which may assist with fat loss. Research indicates that CJC-1295 may exhibit a longer half-life compared to endogenous GHRH. Growth hormone is considered to be able to exert anti-obesity effects through several mechanisms, including lipolysis, utilization of fatty acids as an energy source, and increased fat oxidation. The peptide blend has reportedly also exhibited signs of increased glucose synthesis and reduced glucose uptake, which appears to increase fat utilization and storage. Studies indicate that ghrelin-like peptides such as GHRP-2, “because of its dual effects on ... (hGH) and on energy balance,” may “be a critical hormonal signal of nutritional status to the somatotropic axis, playing a role in integrating energy balance with the growth process.” (7) However, it is important to note that as an apparent ghrelin analog, GHRP-2 may have a similar role, potentially increasing hunger levels. It is hypothesized that the potential appetite-stimulating effects of GHRP-2 are primarily mediated through its interaction with the growth hormone secretagogue receptor (GHSR), specifically GHSR-1a, which is located in various regions such as the hypothalamus, pituitary gland, and stomach. Upon binding to GHSR-1a in the hypothalamus, GHRP-2 is thought to initiate a signal transduction cascade that may lead to the increased production of hunger-inducing neuropeptides, Neuropeptide Y (NPY), and Agouti-related peptide (AgRP). Both NPY and AgRP are suspected to play crucial roles in energy homeostasis and appetite regulation. Concurrently, GHRP-2 could potentially suppress the release of the anorexigenic (appetite-suppressing) hormone, melanocyte-stimulating hormone (α-MSH), thereby tipping the balance towards hunger and stimulating food intake. Additionally, GHRP-2 might influence the mesolimbic reward system, a brain circuitry believed to regulate the desire for palatable food, by activating GHSR-1a. This could hypothetically boost the motivation for food consumption. Moreover, preliminary research suggests that this peptide may induce mild weight gain.(5) Although GHRP-2 seems to predominantly affect appetite through its interaction with GHSR-1a, it is expected to have intricate effects on overall energy homeostasis due to the widespread distribution of GHSRs and the diverse role of ghrelin. Other hormones, neuronal signals, and factors associated with circadian rhythms and physiological states may also modulate its potential appetite-stimulating effects. Ultimately, the peptide may possibly increase energy consumption and negate some of the fat-reducing potential of CJC-1295. Yet, the combination of CJC-1295 & GHRP-2 blend may likely enhance the anabolic potential of each of the compounds. Thus, the blend may have a higher potential for research into weight gain and especially lean muscle gain, rather than fat loss research. This potential is hypothetically mediated by the so-called insulin-like growth factor-1. CJC-1295 & GHRP-2 Blend and Insulin-like Growth Factor 1 (IGF-1) CJC-1295 and GHRP-2 may increase growth hormone levels, thereby binding to specific receptors on liver cells, potentially initiating intracellular signaling events that lead to synthesizing a major anabolic mediator called insulin-like growth factor-1 (IGF-1). The binding of growth hormone might trigger the activation of the Janus kinase-signal transducer and activator of the transcription (JAK-STAT) signaling pathway. The activated STAT proteins may then translocate to the nucleus, where they might bind to specific DNA sequences called response elements, possibly leading to the transcription of the IGF-I gene. The newly synthesized IGF-I is then hypothesized to be released into the circulation, where it could act upon various target tissues. It seems that IGF-I could be a potent growth-promoting hormone that hypothetically mediates several of the growth and anabolic actions of growth hormone. It is proposed to stimulate the growth and proliferation of cells, tissues, and organs, potentially fostering protein synthesis and cellular growth. Research studies suggest that even a brief encounter with CJC-1295 may impact mean plasma growth hormone concentrations, potentially leading to a 2- to 10-fold increase for six days or possibly more. It is hypothesized that the peak of growth hormone levels is typically achieved within 1 to 4 hours after introduction. Additionally, CJC-1295 might lead to observable dependent increases in mean plasma IGF-I concentrations by 1.5- to 3-fold for possibly 9 to 11 days.(8) Post introduction, IGF-I levels are suggested to remain elevated for at least two weeks in test models with higher exposure. After multiple introductions of CJC-1295, mean IGF-I levels appear to remain above baseline for up to 28 days. Interestingly, data suggests a cumulative action after 2 or 3 exposures to the compound, with potentially elevated levels of growth hormone and IGF-I above baseline on day 14 in laboratory experimental models. CJC-1295 & GHRP-2 blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/ Yamamoto D, Ikeshita N, Matsubara T, Tasaki H, Herningtyas EH, Toda K, Iida K, Takahashi Y, Kaji H, Chihara K, Okimura Y. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. Life Sci. 2008 Feb 27;82(9-10):460-6. doi: 10.1016/j.lfs.2007.11.019. Epub 2007 Dec 5. PMID: 18191156. https://pubmed.ncbi.nlm.nih.gov/18191156/ National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 56841945. https://pubchem.ncbi.nlm.nih.gov/compound/56841945 National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 6918245, Pralmorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Pralmorelin. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018 Jan;6(1):45-53. doi: 10.1016/j.sxmr.2017.02.004. Epub 2017 Apr 8. PMID: 28400207; PMCID: PMC5632578. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/ Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30 Laferrère B, Hart AB, Bowers CY. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. Obesity (Silver Spring). 2006 Jun;14(6):1056-63. doi: 10.1038/oby.2006.121. PMID: 16861611; PMCID: PMC2824649. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824649/ Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
MGF IGF-1 EC (5mg)
MGF IGF-1 Ec is the Mehano Growth Factor (MGF) domain made of 24 amino acids, which have been cleaved from the 110 amino acids of IGF-1 Ec alongside other important molecules such as IGF-1 (70 amino acids). Thus, MGF IGF-1 Ec corresponds to the C-terminal 24 residues of the IGF-IEb/Ec pro-peptide. According to research by Janssen et al, the peptide fragment does not measurably induce IGF-1 receptor tyrosine phosphorylation, and does not activate insulin receptors.(1) Instead, the peptide appears to have potential to function as an IGF-related peptide that bypasses classical IGF-1 receptor activation and instead may signal preferentially through ERK pathways, exerting an anabolic potential towards a variety of cell cultures, especially muscle cells. Chemical Makeup Other Known Titles: Mechano-Growth Factor, MGF-Ct24E Molecular Weight: 2971.99 g/mol Molecular Formula: C124H204N42O41S1 Research and Clinical Studies MGF IGF-1 Ec and Muscle Cell Hyperthrophy Most of the research on MGF IGF-1 Ec fragments revolved around muscle cells. One of the most important experiments on the peptide was conducted by Li et al., and suggests that the peptide apparently supports muscle cell hypertrophy.(2) Interestingly, it appears to achieve that by activating Erk5 and Erk1/2 while only weakly and transiently engaging Akt, and it may do so without detectable IGF-1 receptor tyrosine phosphorylation. This profile suggests potential implications of the peptide in studies conducted in laboratory settings aiming to dissect noncanonical, Erk5-centered pathways downstream of IGF-1-derived products, separate from the typical IGF-1–Akt proliferative axis. Li et al. also suggest that in cultured intestinal smooth muscle cells, the peptide may promote an increase in cell volume and total protein content, without stimulating DNA synthesis. This contrasts with IGF-1, which drives proliferation and reduces average cell volume. Because the researchers comment that “Erk5 [mitigation] or MEF2C siRNA blocked smooth muscle-specific gene expression and hypertrophy induced by synthetic MGF”, the peptide may support laboratory study Erk5–MEF2C–dependent transcriptional programs. Future research may interact with the peptide for studying smooth muscle–specific genes such as α-smooth muscle actin, γ-actin, smoothelin, and desmin, all of which appear upregulated by MGF IGF-1 Ec in a MEF2C-dependent manner. MGF IGF-1 Ec and Muscle Cell Aging Kandalla et al. also suggest that MGF IGF-1 Ec may act as a modulator of cellular aging in muscle cells. In myoblasts derived from young satellite cells, repeated short exposures to MGF IGF-1 Ec seemed to mitigate cellular aging for longer in the cell cultures observed in the study.(3) The exposed cells were able to go through slightly more rounds of division, and, importantly, a larger share of them were still actively dividing even after many cycles of growth. In contrast, the control cells largely stopped dividing at that stage. These findings fit with the idea that MGF IGF-1 Ec may briefly interact with the cell-cycle machinery in a way that is at least partly similar to IGF-1 and may interact with stress-response pathways that control when cells permanently stop dividing. However, the authors stress that any interaction with cellular lifespan is modest rather than dramatic. In older muscle cells, MGF IGF-1 Ec did not prolong the period during which cells may keep dividing and may even have accelerated the decline in their division activity. This cellular age-dependent difference in response suggests that MGF IGF-1 Ec may be a helpful tool for experimentally comparing more aged cells versus less aged cellular senescence programs under the same culture conditions. MGF IGF-1 Ec and Muscle Cell Fibrosis Another team of researchers led by Liu et al. suggests that the peptide may reduce histological fibrosis and lower early expression of collagen I and III.(4) This suggests the peptide may have an anti-fibrotic potential in injured muscle cells. In parallel, MGF IGF-1 Ec appeared to decrease “the expression of muscle [cell] inflammatory cytokines (TNF-α, IFN-γ, IL-1β, and TGF-β), chemokines (CCL2, CCL5, and CXCR4), oxidative stress factors (gp91phox) and matrix metalloproteinases (MMP-1, MMP-2, MMP-9, MMP-10, and MMP-14)”, thus hinting at diminished NADPH oxidase–related oxidative stress. The researchers suggested that the peptide may have also altered the expression of several MMPs involved in extracellular matrix turnover. Taken together, the research by Liu et al suggests that the MGF IGF-1 Ec fragment may prove to be a relevant laboratory tool to investigate and possibly modulate the balance between muscular tissue repair and fibrotic scarring. MGF IGF-1 Ec and Muscle Cell Death Experiments by Doroudian et al. have also explored MGF IGF-1 Ec as a potential modulator of cellular death.(5) According to researchers, the anti-apoptotic potential of the peptide was clear in the mammalian myocyte cultures exposed to low oxygen environments observed in laboratory settings. The researchers observed less DNA fragmentation and increased expression of the pro-survival gene Bcl-2 compared with hypoxic control cells. These findings suggest that the peptide may prove to be relevant experimentally as a tool to probe survival pathways in muscle cells under controlled stress. Mechanistically, the upregulation of Bcl-2 suggests a possible engagement of intrinsic survival signaling, likely intersecting with mitochondrial pathways. Thus, the data position MGF IGF-1 Ec as a potential research reagent for reducing apoptosis in stressed muscle cells and for systematically studying how IGF-1–related peptides may promote cell survival. MGF IGF-1 Ec and Cartilage Cells In further research, the team of Liu et al. also investigated the potential of the MGF IGF-1 Ec fragment in other cell cultures, such as cartilage cells.(6) The data summarized by the researchers suggests that MGF IGF-1 Ec may support several key processes around defect zones that form when cartilage cells are mechanically overloaded or otherwise stressed. In progenitor cell cultures, the peptide apparently potentiated TGF-β3–induced chondrogenesis, supporting Col2 and aggrecan expression while suppressing Col1. This suggests that the peptide may be a possible cofactor in systems that model matrix quality, thus stimulating hyaline rather than fibrocartilage-like cellular production. In damaged or hypoxic chondrocyte cultures, the peptide was suggested to reduce pro-fibrotic and catabolic markers (Col1, MMP1/3/13, HIF-1α) and to increase Col2, often via PI3K–Akt and MEK–ERK1/2 signaling. The researchers posited that MGF IGF-1 Ec may also act as a factor that promotes migration of chondrocytes and mesenchymal cells under overload or severe hypoxia, apparently through RhoA–YAP activation and associated focal adhesion and cytoskeletal reorganization. This gives it potential relevance in assays of cell motility, cytoskeletal mechanics, and mechanotransduction. Some of the data analyzed by the researchers also suggest that MGF IGF-1 Ec may dampen inflammatory signaling by apparently downregulating IL-1β, TNF-α, and TGF-β. Moreover, the peptide may mitigate apoptosis by shifting Bcl-2/Bax balance and reducing caspase-3/-8 and CHOP, making it a candidate reagent for dissecting the potential interactions between mechanical stress, ER stress/UPR, and programmed cell death in cartilage cell cultures. MGF IGF-1 Ec and Bone Cells Research by Deng et al, also suggests that MGF IGF-1 Ec may act as a potential osteoanabolic signal with a distinct profile from IGF-1.(7) The researchers conducted experiments with MC3T3-E1 osteoblast-like cells, and noted that the peptide may stimulate proliferation more strongly than full-length MGF or IGF-1, with ~1.4-fold higher pro-proliferative activity than IGF-1. Mechanistically, the peptide may push cells into S and G2/M phases, doubling the number of cells synthesizing DNA and increasing the number of cells entering mitosis about 5-fold. This potential was coupled with robust activation of the MAPK/ERK1/2 pathway. Once again, the researchers observed that blocking ERK almost abolished the proliferative response, whereas PI3K mitigation had minimal meaningful interaction, highlighting that MGF IGF-1 Ec may act via an ERK-dominant, IGF-1 receptor-independent mechanism. Further laboratory research suggested that the peptide may increase callus formation, cortical bridging, and disappearance of the fracture line, with a subset of defects radiographically united by week 8. Histologically, the research models appeared to have increased levels of lamellar bone, restored marrow cavity, higher vascularity and osteoid formation, and fewer fibroblasts compared with controls—consistent with faster, more organized bone remodeling rather than fibrous non-union. With this in mind, the peptide may be viewed as a selective supporter of osteoblast proliferation and early bone regeneration, acting through MAPK/ERK signaling and offering a compact, synthetic tool to model or potentially augment bone cell regeneration in laboratory systems. MGF IGF-1 Ec and Neural-like Cells Research by Quesada et al. suggests that MGF IGF-1 Ec may support cell survival, reduce apoptotic markers, and maintain mitochondrial integrity in SH-SY5Y neuroblastoma cells found in mammalian models with mitochondrial dysfunction and increased apoptosis due to neurotoxin exposure. Mechanistically, this interaction has been linked to upregulation of heme-oxygenase-1 (HO-1), which, when mitigated, appears to negate the peptide’s protective potential. Further research has similarly suggested that MGF IGF-1 Ec may reduce loss of vulnerable neuronal populations and preserve motor performance under neurotoxic or degenerative conditions. Moreover, the peptide may mimic a stress-protective, ERK-linked stimulus in neural-like cells. MGF IGF-1 Ec peptide is available for research and laboratory purposes only. Please review our Terms and Conditions before ordering. References: Janssen JA, Hofland LJ, Strasburger CJ, van den Dungen ES, Thevis M. Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations. PLoS One. 2016 Mar 18;11(3):e0150453. doi: 10.1371/journal.pone.0150453. PMID: 26991004; PMCID: PMC4798685. Li C, Vu K, Hazelgrove K, Kuemmerle JF. Increased IGF-IEc expression and mechano-growth factor production in the intestinal muscle of fibrostenotic Crohn's disease and smooth muscle hypertrophy. Am J Physiol Gastrointest Liver Physiol. 2015 Dec 1;309(11):G888-99. doi: 10.1152/ajpgi.00414.2014. Epub 2015 Oct 1. PMID: 26428636; PMCID: PMC4669353. Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev. 2011 Apr;132(4):154-62. doi: 10.1016/j.mad.2011.02.007. Epub 2011 Feb 25. PMID: 21354439. Liu X, Zeng Z, Zhao L, Chen P, Xiao W. Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection. Front Physiol. 2019 May 17;10:601. PMID: 31164836; PMCID: PMC6534059.doi:10.3389/fphys.2019.00601 Doroudian G, Pinney J, Ayala P, Los T, Desai TA, Russell B. Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes. Biomed Microdevices. 2014 Oct;16(5):705-15. doi: 10.1007/s10544-014-9875-z. PMID: 24908137; PMCID: PMC4418932. Liu Y, Duan M, Zhang D, Xie J. The role of mechano growth factor in chondrocytes and cartilage defects: a concise review. Acta Biochim Biophys Sin (Shanghai). 2023 May 12;55(5):701-712. PMID: 37171185; PMCID: PMC10281885.doi:10.3724/abbs.2023086 Deng M, Zhang B, Wang K, Liu F, Xiao H, Zhao J, Liu P, Li Y, Lin F, Wang Y. Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits. Int Orthop. 2011 Jul;35(7):1099-106. doi: 10.1007/s00264-010-1141-2. Epub 2010 Nov 6. PMID: 21057789; PMCID: PMC3167400. Quesada A, Micevych P, Handforth A. C-terminal mechano growth factor protects dopamine neurons: a novel peptide that induces heme oxygenase-1. Exp Neurol. 2009 Dec;220(2):255-66. doi: 10.1016/j.expneurol.2009.08.029. Epub 2009 Sep 6. PMID: 19735655. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Pentapeptide-18 (Leuphasyl) (200mg)
Pentapeptide-18 is a synthetic peptide composed of five amino acids (H-Tyr-Ala-Gly-Phe-Leu-OH) that were developed to mimic the natural process of suppressing muscle contractions, consequently reducing the development and depth of wrinkling along the epidermal barrier. Pentapeptide-18 has been hypothesized by researchers to interact with the neuroreceptors in the skin, potentially inhibiting the release of acetylcholine, a neurotransmitter that triggers muscle contractions.(1) Pentapeptide-18 has also been suggested to impact skin cell function. It may potentially help to increase skin barrier elasticity through the stimulation of key proteins collagen and elastin. Both these proteins are considered to be a crucial component of the skin's extracellular matrix, and their production tends to decrease over time. Chemical Makeup(2) Molecular Formula: C29H39N5O7 Molecular Weight: 569.65 g/mol Other Known titles H-Tyr-Ala-Gly-Phe-Leu-OH, Leuphasyl Research and Clinical Studies Pentapeptide-18 and Wrinkling, Skin Structure A 2014 study investigated the potential of Pentapeptide-18 (Leuphasyl) in reducing the depth and length of wrinkles and creases along the stratum corneum of the skin. This study evaluated the impact on moderate to severe wrinkles exposed to a Pentapeptide-18 formulation twice a day for 28 days. Digital imaging and silicone replicas were used to determine an apparent reduction in the depth of the wrinkles, with an average reduction of 11.31%. As per Anca O. Dragomirescu et al., “Leuphasyl is an active synthesis peptide… The efficiency of this molecule is evidently inferior to botulinum toxin … but it [may be] free from side effects and it confers an aspect of wrinkles’ attenuation.” (1) Research indicates that Pentapeptide-18 may be highly specific. Clinical studies have suggested a statistically significant reduction of 2% to 9% in the appearance of wrinkles. In a randomized, double-blind, placebo-controlled study, researchers evaluated the depth of wrinkles and skin smoothness following peptide exposure using various methods such as skin imaging, dermatological assessments, and subjective self-assessments. The results suggested an overall reduction in the depth of wrinkles and increased skin smoothness after four weeks.(3) Pentapeptide-18 and Fine Lines Scientists posit that Pentapeptide-18 may reduce fine lines, due to its potential ability to decrease glutamate release by 11%. This potential was apparently noticed following two months of experimentation in one study. This reduction suggests that Pentapeptide-18 might influence neurotransmitter pathways, possibly involved in the control of muscle contractions beneath the skin. The modulation of glutamate, a key excitatory neurotransmitter, might hypothetically lead to decreased muscular activity, thereby reducing the formation and depth of fine lines.(4) In addition to reducing glutamate, Pentapeptide-18 may also suppress acetylcholine. The potential mechanism suggested involves decreased acetylcholine secretion within the synaptic cleft. This hypothesis is grounded on observing enkephalins’ typical function in modulating neurotransmitter release. Enkephalins, which are part of the endogenous opioid peptides, are believed to potentially inhibit neurotransmitter release, and this property is thought to possibly extend to the action of Pentapeptide-18. Specifically, the interaction between Pentapeptide-18 and neural receptors might lead to an inhibition of acetylcholine release. This inhibition may be mediated through the modulation of calcium influx into presynaptic neurons. Calcium plays a crucial role in the exocytosis of neurotransmitters, and its reduction within neurons is often linked to decreased neurotransmitter secretion. Therefore, it is conceivable that Pentapeptide-18 may contribute to this pathway, possibly by mimicking the regulatory actions of enkephalins on calcium channels.(5) Pentapeptide-18 and Melanogenesis Park et al. (2020) explored the potential actions of D-tyrosine-containing cosmetic Pentapeptide-18 derivatives on melanogenesis.(6) The modifications to these peptides involved substituting the N-terminal L-tyrosine with D-tyrosine or appending L/D-tyrosine at the C-terminus. This research utilized melanoma MNT-1 cells to evaluate these possibilities. The findings tentatively suggest that alterations in the peptide structure may potentially affect melanogenesis. It is hypothesized that the presence of D-tyrosine, particularly when located at the C-terminal end of the peptide chain, might contribute to a reduction in melanogenesis. This observation was notable in Pentapeptide-18 analogs featuring C-terminal D-tyrosine. The results seem to indicate that the positioning and orientation of the tyrosine residues within the peptide might play a significant role. D-tyrosine, the enantiomer of the naturally occurring L-tyrosine, might conceivably modify the peptide’s interactions with enzymes or receptors involved in melanin synthesis, potentially leading to decreased melanin production in the cells. Pentapeptide-18 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References Dragomirescu, A. O., Andoni, M., Ionescu, D. & Andrei, F. The Efficiency and Safety of Leuphasyl—A Botox-Like Peptide. Cosmetics 1, 75–81 (2014). https://www.mdpi.com/2079-9284/1/2/75 Leucine,L-tyrosyl-L-alanylglycyl-L-phenylalanyl National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 44568, Pentapeptide-18. Puig, A., Garcia-Anton, J., Perez, R. & Mangues, M. Eyeseryl and Leuphasyl: Synthetic Peptides as Advanced Cosmetic Actives. Available at http://www.cosmeticsciencetechnology.com/companies/articles/821.pdf. Schagen SK. Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017; 4(2):16. https://doi.org/10.3390/cosmetics4020016 Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020 Oct 30;8:572923. doi: 10.3389/fchem.2020.572923. PMID: 33195061; PMCID: PMC7662462. Park J, Jung H, Jang B, Song HK, Han IO, Oh ES. D-tyrosine adds an anti-melanogenic effect to cosmetic peptides. Sci Rep. 2020 Jan 14;10(1):262. doi: 10.1038/s41598-019-57159-3. PMID: 31937863; PMCID: PMC6959337. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.